Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Double Blind Benralizumab	0	144
Total, all-cause mortality	Double Blind Placebo	0	143
Total, all-cause mortality	Double Blind Benralizumab First, Then Open Label Benralizumab	0	122
Total, all-cause mortality	Double Blind Placebo First, Then Open Label Benralizumab	0	125
Total, other adverse events	Double Blind Benralizumab	78	144
Total, other adverse events	Double Blind Placebo	59	143
Total, other adverse events	Double Blind Benralizumab First, Then Open Label Benralizumab	37	122
Total, other adverse events	Double Blind Placebo First, Then Open Label Benralizumab	33	125
Total, serious adverse events	Double Blind Benralizumab	12	144
Total, serious adverse events	Double Blind Placebo	12	143
Total, serious adverse events	Double Blind Benralizumab First, Then Open Label Benralizumab	6	122
Total, serious adverse events	Double Blind Placebo First, Then Open Label Benralizumab	9	125

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04157335/event-totals